Sanara MedTech Returns to Profitability with Strong Q1 Revenue Growth
SMTI sits 27% above its 52-week low of $16.047 on elevated volume (3.3× avg).
Summary
Sanara MedTech Inc. reported a return to net profitability in Q1 2026, driven by 19% revenue growth in its core surgical business and the successful discontinuation of its loss-making THP segment.
Key Events · Earnings and Guidance · SMTI
-
Return to Net Profitability
The company achieved net income from continuing operations of $0.4 million in Q1 2026, a significant improvement from a net loss of $0.6 million in Q1 2025. Net income attributable to shareholders was $0.46 million, compared to a $3.53 million loss in the prior year.
-
Strong Revenue Growth
Net revenue increased by 19% to $27.8 million in Q1 2026, up from $23.4 million in Q1 2025, primarily driven by increased sales of soft tissue repair products like CellerateRX Surgical and BIASURGE.
-
Adjusted EBITDA Surges
Adjusted EBITDA grew by 58% to $4.3 million in Q1 2026, compared to $2.7 million in Q1 2025, reflecting improved operational performance.
-
Strategic Shift Validated
The wind-down of the loss-making Tissue Health Plus (THP) segment is substantially complete, and related earnout liabilities for the CarePICS Acquisition and Applied Asset Purchase have been reduced to zero, removing future financial obligations and focusing the company on its profitable surgical market.
Analysis · SMTI · Industrial Applications And Services
Sanara MedTech Inc. reported a significant financial turnaround in Q1 2026, achieving net income from continuing operations of $0.4 million, a substantial improvement from a $0.6 million net loss in the prior year. This positive shift is driven by robust 19% revenue growth in its continuing surgical operations and a 58% increase in Adjusted EBITDA. The company has also successfully wound down its loss-making Tissue Health Plus (THP) segment, eliminating associated earnout liabilities and streamlining its focus on the profitable surgical market. This report validates the company's strategic realignment and demonstrates improved financial health and operational efficiency.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMTI was trading at $20.44 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $187.3M. The 52-week trading range was $16.05 to $35.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.